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Edit B. Olasz1, Jooyoung Roh2,4, Carole L. Yee2, Ken Arita3, Masashi Akiyama3, Hiroshi Shimizu3,
Jonathan C. Vogel2 and Kim B. Yancey1
Bullous pemphigoid antigen 2 (BPAG2) is targeted by autoantibodies in patients with bullous pemphigoid (BP),
and absent in patients with one type of epidermolysis bullosa (OMIM #226650). A keratin 14 promoter construct
was used to produce transgenic (Tg) mice appropriately expressing human BPAG2 (hBPAG2) in murine
epidermal basement membrane (BM). Grafts of Tg skin placed on gender-matched, syngeneic wild type (Wt) or
major histocompatibility complex I (MHC I)/ mice elicited IgG that bound human epidermal BM and BPAG2.
Production of such IgG in grafted mice was prompt (detectable within 1672 days), robust (titerX1,280), durable
(presentX380 days), and correlated with the involution and loss of Tg skin grafts. MHC II/ mice grafted with
Tg skin did not develop anti-hBPAG2 IgG or graft loss indicating that MHC II:CD4þ T cell interactions were
crucial for these responses. Tg skin grafts on Wt mice developed neutrophil-rich infiltrates, dermal edema,
subepidermal blisters, and deposits of immunoreactants in epidermal BM. This model shows fidelity to
alterations seen in patients with BP, has relevance to immune responses that may arise in patients with
epidermolysis bullosa following BPAG2 gene replacement, and can be used to identify interventions that may
block production of IgG against proteins in epidermal BM.
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INTRODUCTION
Bullous pemphigoid antigen 2 (BPAG2) is a type II
transmembrane collagen (specifically, type XVII collagen)
associated with hemidesmosome-anchoring filament com-
plexes in basal keratinocytes (Franzke et al., 2003, 2005; Van
den Bergh and Giudice, 2003). BPAG2 consists of an
intracellular domain that associates with BPAG1, integrin
subunit b4, and plectin, a short, single-pass transmembrane
segment, and a long extracellular domain that consists of 15
interrupted collagenous domains assembled into a homo-
trimeric triple helix. Rotary shadowing of purified BPAG2
images its intracytoplasmic region as a globular head and its
extracellular region as a central rod with an adjoining flexible
tail (Hirako et al., 1996). The latter extracellular regions
correspond to the largest (i.e., domain 15) and the remaining
(i.e., domains 1–14) collagenous segments of the protein,
respectively. Immunoelectron microscopy studies indicate
that the rod domain of BPAG2 spans the lamina lucida, while
its C-terminus loops through the lamina densa back into the
lamina lucida (Masunaga et al., 1997; Nonaka et al., 2000).
The C-terminal portion of BPAG2 interacts with laminin 5 at
the interface of the lamina lucida and the lamina densa
(Masunaga et al., 1997; Tasanen et al., 2004).
Autoantibodies from patients with the autoimmune sub-
epidermal blistering disease bullous pemphigoid (BP) typi-
cally target the 16th noncollagenous domain of BPAG2 (i.e.,
NC16A) (Giudice et al., 1993). Passive transfer of experi-
mental IgG (specifically, rabbit IgG) developed against the
murine homolog of human NC16A elicits clinical, histologic,
and immunopathologic alterations in neonatal BALB/c mice
that mimic those seen in patients with BP (Liu et al., 1993).
IgG-induced blister formation in this animal model is
dependent upon complement activation, degranulation of
dermal mast cells, and generation of neutrophil-rich infil-
trates – the latter providing sufficient amounts of unrestrained
neutrophil elastase to degrade BPAG2 and produce sub-
epidermal blisters in vivo (Liu et al., 2000). This thoroughly
characterized experimental murine model is widely regarded
to provide proof of concept that IgG anti-NC16A autoanti-
bodies in patients with BP are pathogenic (Yancey, 2005).
While such acquired alterations in BPAG2 are held respon-
sible for the pathogenesis of BP, patients with an inherited
subepidermal blistering disease termed generalized atrophic
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typically possess null mutations in the gene encoding BPAG2
(i.e., COL17A1) (McGrath et al., 1995; Pohla-Gubo et al.,
1995; Darling et al., 1997b). Patients with GABEB character-
istically demonstrate a complete lack of BPAG2 in epidermal
basement membrane (BM), skin fragility, subepidermal
blisters at sites of friction or trauma, alopecia, dystrophic
nails, and dental enamel hypoplasia – a series of clinical
findings that further attest to the key role that BPAG2 plays in
epidermal adhesion and homeostasis (Darling et al., 1997a;
Van den Bergh and Giudice, 2003).
Given the pivotal role that BPAG2 plays in these inherited
and acquired subepidermal blistering diseases, it has been
hypothesized that successful gene replacement in patients
with GAGEB may lead to unwanted immune responses to the
transgene thus yielding a phenotype that mimics BP. To
explore this hypothesis and develop an animal model in
which experimental immune responses to human BPAG2
(hBPAG2) can be developed, modulated, and/or blocked in
vivo, hBPAG2 transgenic (Tg) mice were created, characteri-
zed, and studied in a series of skin grafting experiments.
RESULTS
Transient transfection studies
An immortalized GABEB keratinocyte line transfected with
the hBPAG2 cDNA transgene construct showed bright,
diffuse cytoplasmic staining for BPAG2 by immunofluores-
cence (IF) microscopy (Figure 1a). In contrast, GABEB
keratinocytes transfected with the same construct lacking
hBPAG2 cDNA (i.e., cells transfected with a ‘‘mock’’
construct and subjected to selection in the same manner)
showed no staining for BPAG2 (Figure 1b). Immunoblot
studies of extracts from transgene- and mock-transfected
GABEB keratinocytes identified hBPAG2 as a 180 kDa
polypeptide in the former (Figure 1c, lane 4), but not the
latter (Figure 1c, lane 2).
Generation of hBPAG2 Tg mice
Fifty-five mice representing candidates for chimeric status
were screened by Southern blotting using a radiolabeled
fragment of the hBPAG2 cDNA transgene construct. Five
mice showed evidence of transgene integration; of these, four
chimeras yielded founder lines for subsequent studies. DNA
from the tails of founder mice was amplified by PCR using a
forward primer specific to the human keratin 14 promoter
and a reverse primer specific to hBPAG2 cDNA. Two founder
lines (specifically lines D and E) expressed the transgene in
murine epidermal BM at highest levels by IF microscopy.
These two lines were expanded to yield numerous hetero-
zygous (þ /) and homozygous (þ /þ ) mice (i.e., genera-
tions XF8). The genotype of initial þ /þ Tg mice in lines D
and E was confirmed by breeding these lines with wild-type
(Wt) mice and showing that all progeny received a copy of
the hBPAG2 transgene. These confirmatory experiments
provided conclusive evidence that only þ /þ mice were
retained for expansion of our Tg colony. All Tg mice were
phenotypically normal; all experiments reported herein used
mice derived from founder line D. Fluorescent in situ
hybridization studies showed that the hBAPG2 transgene
was integrated into chromosome 15 (specifically, at 15F2-3)
in mice of founder line D. This portion of the mouse genome
is devoid of elements known to influence or govern
immunologic or inflammatory reactions. Of note, the gene
for murine COL17A1 is positioned on chromosome 19.
hBPAG2 Tg mice express the transgene in epidermal BM
Light microscopy studies of skin from þ / and þ /þ Tg
mice were identical to Wt controls. Biopsies of trunk, ear, and
tail skin from these mice were examined in IF microscopy
studies using: (1) rabbit antiserum specific for the C-terminal
portion of hBPAG2 (Masunaga et al., 1997); (2) normal rabbit
serum (control); (3) HD-18, a murine mAb specific for the
NC16A-2.5 region of hBPAG2 (Pohla-Gubo et al., 1995); and
(4) an isotype-matched, irrelevant murine mAb (control). þ /þ
Tg mice showed expression of hBPAG2 in epidermal BM in
the same manner this protein is expressed in normal human
skin. Such reactivity in Tg skin was identified using both rabbit
antiserum specific for hBPAG2 (Figure 1d), as well as a murine
mAb specific for its NC16A domain. IgG from patients with BP
also bound the epidermal BM of Tg mice. hBPAG2 was not
apparent in the cytosol of basal or suprabasal keratinocytes of
Tg mice. Immunoblot studies of epidermal extracts from Tg
and Wt mice found that hBPAG2 was expressed as a 180 kDa
protein in the former, but not the latter (data not shown).
Immunogold studies
The same rabbit hBPAG2 antiserum shown in Figure 1d was
used to perform immunogold electron microscopy studies of
cryopreserved human (Figure 2a), Tg (Figure 2b), and Wt
(Figure 2c) skin to assess the expression and localization of
hBPAG2. The cryopreservation and cryofixation techniques
applied in these studies retained the immunoreactivity of
structural proteins with sufficient preservation of morphology
to allow high resolution of epitopes in epidermal BM. In these
studies, the C-terminus of hBPAG2 in human and Tg skin was
localized to the superior aspect of the lamina densa at its
interface with the lamina lucida (Figure 2a and b). Expression
of hBPAG2 in þ /þ Tg skin was somewhat less than that in
human skin. There was no ectopic localization or aggregation
of hBPAG2 in Tg skin. Rabbit hBPAG2 antiserum showed no
reactivity to Wt skin (Figure 2c).
Wt mice grafted with Tg skin develop anti-hBPAG2 IgG
The studies described above indicated that hBPAG2 was
expressed with appropriate localization and immunoreacti-
vity in the epidermal BM of Tg mice, and that such expression
did not impair epidermal morphogenesis, adhesion, or
differentiation. To determine if the skin of Tg mice would
elicit immune reactions in Wt mice, full-thickness 1 cm2
grafts from the tails of Tg mice were placed onto the flanks of
gender-matched, syngeneic Wt recipients. As controls, tail
skin from Wt donors was grafted onto the opposing flank of
Tg graft recipients (or alternate gender-matched, syngeneic
Wt mice). Tg and Wt skin (from tail or flank, the former used
in the results presented herein) engrafted equally. To date,
over 100 individual skin grafts have been placed on various
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recipients; the experimental series shown herein are repre-
sentative of results consistently documented in this body of
work.
Longitudinal studies found that Wt mice grafted with Tg
skin consistently developed IgG that bound epidermal BMs in
human and Tg skin, but not skin from Wt mice (Figure 3a).
Production of such IgG in Wt mice was prompt (detectable
within 1672 days), robust (titer X1,280), and durable
(present 4380 days) (Figure 3b). This IgG was present in
serum from each of 32 Wt mice grafted with Tg skin,
exclusively reactive with the epidermal side of 1 M NaCl split
human skin, and capable of fixing C3 to epidermal BM at
dilutions as high as 160. Control experiments demonstrated
that sera from Wt mice grafted only with gender-matched,
syngeneic Wt skin had no evidence of IgG reactive with
epidermal BMs in human, Tg, or Wt skin (Figure 3a, n¼ 4,
recipients followed for as long as 200 days after graft
placement). These studies consistently demonstrated that
1
Rabbit anti-hBPAG2 Normal rabbit serum
Normal 
human
skin
hBPAG2 
Tg skin
Wt 
skin
2 3 4
Figure 1. The hBPAG2 cDNA transgene construct expressed protein of appropriate immunoreactivity and molecular weight in an immortalized GABEB
keratinocyte line and Tg skin. (a) An immortalized GABEB keratinocyte line transfected with the transgene construct showed bright, diffuse cytoplasmic
staining for hBPAG2 in IF microscopy studies. (b) In contrast, GABEB keratinocytes transfected with the same construct lacking hBPAG2 cDNA (i.e., cells
transfected with a ‘‘mock’’ construct and subjected to selection in the same manner) showed no staining for hBPAG2. Nonimmune rabbit sera showed no
reactivity to these cells (data not shown). (c) Immunoblot studies of extracts from transgene- and mock-transfected GABEB keratinocytes identified hBPAG2 as a
180 kDa polypeptide in the former (lane 4) but not the latter (lane 2). Immortalized GABEB keratinocytes transfected with the same hBPAG2 cDNA in an
alternate vector (i.e., pcDNA3) served as an additional positive control (lane 3) as did extracts of normal HKs (lane 1). Nonimmune rabbit sera showed
no reactivity to these extracts (data not shown). Ticks in the left margin correspond to 250 and 116 kDa molecular weight markers; the arrow points to a
180 kDa band corresponding to hBPAG2. (d) Tg mice express hBPAG2 in epidermal BM. Cryosections of skin from man, a Tg mouse, and a Wt mouse
(top, middle, and bottom panels, respectively) were studied by IF microscopy using rabbit antiserum developed against the C-terminus of hBPAG2
(Masunaga et al., 1997) (left panels) or normal rabbit serum (control, right panels). hBPAG2 was specifically expressed in the epidermal BMs of human
and Tg skin (arrows, top and middle left panels); this antiserum showed no specific reactivity to the skin of a Wt mouse (bottom left panel). There was no
cytosolic, suprabasal, or intradermal expression of hBPAG2 in any skin samples. Control IF microscopy studies using normal rabbit serum were negative
(right panels).
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Tg skin grafts elicited specific immune responses in Wt mice,
that such reactions included humoral immune responses, and
that such responses were characterized by immunoglobulin
class switching.
To determine if anti-BM IgG production was dependent
upon major histocompatibility complex I (MHC I):CD8þ
T cell or MHC II:CD4þ T-cell interactions, Tg skin was
grafted onto gender-matched MHC I/ and MHC II/
mice, recipients otherwise syngeneic with donors. The
kinetics and duration of anti-BM IgG production in
MHC I/ recipients was virtually identical to that seen in
Wt recipients (Figure 3b). In contrast, MHC II/ recipients
did not develop anti-BM IgG (n¼ 10, four recipients followed
for as long as 330 days after graft placement) (Figure 3b).
Anti-BM IgG also failed to develop in MHC II/ mice that
received two separate Tg skin grafts applied 30 days apart.
These results indicated that anti-BM IgG production in grafted
mice was dependent upon MHC II:CD4þ T-cell interactions.
To define the precise reactivity of anti-BM IgG in Wt mice
grafted with Tg skin, a series of immunoblot and immuno-
precipitation experiments were performed. These experi-
ments showed that the sera of these graft recipients contained
IgG that bound hBPAG2 and that such reactivity included
binding to NC16A (Figure 4a). Adsorption of immune mouse
sera with recombinant NC16A removed all reactivity against
this peptide, yet failed to impair the reactivity of immuno-
adsorbed sera with human epidermal BM by IF microscopy
(data not shown) or full-length hBPAG2 in human keratino-
cytes (HK) extracts (Figure 4a). Sera from grafted mice
showed no evidence of reactivity to other HK proteins
including BPAG1 (Figure 4b).
CD4þ T cells from Wt mice grafted with Tg skin demonstrated
specific and dose-related proliferative responses to NC16A-GST
in vitro
CD4þ T cells purified from axillary and inguinal lymph
nodes of Wt mice 10 days previously grafted with Tg skin
(both flanks) were assessed for secondary proliferative
Normal 
human
skin
LL
LL
LL
LD
LD
LD
HD
HD
HD
hBPAG2 
Tg skin
Wt 
skin
Figure 2. hBPAG2 displayed normal ultrastructural localization in the
epidermal BM of Tg skin. Post-embedding immunogold electron microscopy
studies localized 5 nm gold particles staining hBPAG2 within the superior
aspect of the lamina densa in (a) human and (b) Tg skin (arrows). This staining
was consistent with that reported for this antiserum (Masunaga et al., 1997).
Expression of hBPAG2 in Tg skin was somewhat less than that in human skin.
There was no ectopic localization or aggregation of hBPAG2 in Tg skin.
(c) Anti-hBPAG2 antiserum showed no specific reactivity to the skin of a
Wt mouse. HD, hemidesmosome; LL, lamina lucida; LD, lamina densa.
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Figure 3. Tg skin grafts elicited anti-BM IgG in Wt and MHC I/ mice. (a)
Tg skin grafts placed on Wt recipients elicited IgG that bound epidermal BMs
in human and Tg skin (arrows, top and middle left panels), but not the skin of
a Wt mouse (bottom left panel). Development of anti-BM IgG was unrelated
to the grafting procedure (right panels). (b) Longitudinal studies showed that
Tg skin grafts placed on Wt (solid circles) and MHC I/ (solid squares)
recipients elicited high (640–2,560) and durable (lasting X270 days) titers of
anti-BM IgG that consistently appeared in the circulation of recipients 14–18
days after grafting. MHC II/ mice (solid triangles) grafted with Tg skin did
not develop anti-BM IgG; n¼4 per group in this longitudinal study that was
representative of the aggregate work.
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responses to recombinant NC16A-GST (Figure 5). CD4þ T
cells from graft recipients (n¼10) demonstrated dose-related
proliferative responses to NC16A-GST, but not to equivalent
amounts of glutathione-S-transferase (GST) alone or phos-
phate-buffered saline (PBS). CD4þ T cells from Wt mice
grafted with Wt skin (controls, n¼ 10) did not show
proliferative response to NC16A-GST, GST, or PBS (data
not shown).
Wt and MHC I/ mice lost Tg skin grafts with identical
kinetics, while MHC II/ mice retained grafts of Tg skin
Grafts of Wt skin placed on gender-matched, syngeneic Wt
recipients (controls) survived for their entire period of study
(n¼16, four recipients followed for as long as 200 days after
graft placement, data not shown). In contrast, Tg skin grafts
showed notable involution 15–23 days following placement
on gender-matched, syngeneic Wt (n¼12) and MHC I/
(n¼12) recipients (Figure 6). The kinetics of graft involution
and loss were identical in Wt and MHC I/ recipients
(median graft survival time¼3074 days). These studies
showed that acceleration of graft involution consistently
correlated with production of anti-hBPAG2 IgG and that graft
loss in this model was not mediated by CD8þ T cells
(Figure 6). Interestingly, Tg skin grafts placed on ‘‘immune’’
Wt mice (i.e., Wt mice previously grafted with Tg skin and
displaying anti-hBPAG2 IgG) were typically lost within 10–15
days – a profile virtually identical to that observed once anti-
hBPAG2 IgG first appeared in Wt mice grafted with Tg skin
(Figure 6). Accelerated graft loss was not observed in Wt mice
twice grafted with gender-matched, syngeneic Wt skin. Of
note, Tg skin grafts placed on MHC II/ mice retained their
original viability and size for their entire period of study
HK extract GST-NC16A
230
180
180
1 2 3
1 2 3 4 5 6
37
4
Figure 4. IgG in the sera of Wt mice grafted with Tg skin specifically
bound hBPAG2. (a) IgG in the sera of Wt mice grafted with Tg skin
specifically bound hBPAG2 in extracts of cultured HKs as well as
recombinant NC16A-GST (lanes 1 and 4, respectively). While preadsorption
of immune sera with recombinant NC16A-GST completely removed all
reactivity to this fusion protein (lane 5), immunoadsorbed immune sera still
bound hBPAG2 (lane 2), indicating that epitopes other than NC16A are also
targeted by such IgG. Normal mouse serum did not show any reactivity to
hBPAG2 or NC16A-GST (lanes 3 and 6, respectively). Results were confirmed
in three separate experiments. Markers in the left margins indicate Mr 103.
(b) Immunoprecipitation studies of biosynthetically radiolabeled HK extracts
showed that sera from Wt mice grafted with Tg skin (representative example,
lane 1) contained IgG that bound BPAG2 but not BPAG1 – the former
identified as a 180 kDa protein that comigrated with BPAG2
immunoprecipitated by serum from a patient with BP (lane 3). Serum from a
Wt mouse grafted with Wt skin (lane 2) as well as serum from a normal
volunteer (lane 4) bound no specific HK proteins in these
immunoprecipitation studies. Markers in the right margin indicate Mr 103.
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Figure 5. CD4þ T cells from Wt mice grafted with Tg skin demonstrated
specific and dose-related proliferative responses to NC16A-GST in vitro. Ten
days after receiving grafts of Tg skin, axillary and inguinal lymph nodes of Wt
mice were harvested and processed to yield CD4þ T cells that were placed
in culture and assessed for secondary proliferative responses to various
concentrations of recombinant NC16A-GST (solid circles), recombinant GST
alone (solid squares), or PBS (solid triangles). g-irradiated splenocytes from
naı¨ve, syngeneic Wt mice were used as stimulator cells. CD4þ T cells from
graft recipients proliferated specifically to NC16A-GST but not to GST alone
or PBS. CD4þ T cells from Wt mice grafted with Wt skin did not show
proliferative response to NC16A-GST, GST, or PBS (data not shown); n¼ 10
per group.
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Figure 6. Wt and MHC I/ mice lost Tg skin grafts with identical kinetics,
while MHC II/ mice retained grafts of Tg skin. Tail skin was harvested
from Tg and Wt mice and grafted onto the opposite flanks of age- and gender-
matched Wt (solid circles), MHC I/ (solid squares), MHC II/ (solid
triangles), and ‘‘immune’’ Wt (open circles) recipients. Bandages were
removed on day 7; thereafter, mice were examined daily for 30 days then
weekly to assess graft viability and size. Skin grafts were graded as ‘‘lost’’
if their area became p20% of their original size (McFarland et al., 2003).
These longitudinal studies demonstrated that grafts of Tg skin on Wt and MHC
I/ recipients displayed accelerated involution at days 15–23 (i.e., the
approximate time circulating anti-hBPAG2 IgG became detectable in
recipients), and complete loss by days 28–30. Tg skin placed on ‘‘immune’’
Wt recipients (i.e., mice previously grafted with Tg skin and displaying
anti-hBPAG2 in their circulation) were typically lost within 15 days –a profile
like that observed once anti-hBPAG2 IgG first appeared in Wt mice grafted
with Tg skin. Tg skin grafts placed on MHC II/ recipients retained their
viability and size for their entire period of study; n¼4 per group in this
longitudinal study that was representative of the aggregate work.
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(n¼10, four recipients followed for as long as 330 days)
(Figure 6). These results indicated that Tg graft loss in this
model was dependent on MHC II:CD4þ T-cell interactions
just as was production of hBPAG2-specific IgG.
Tg skin grafts on Wt mice developed in situ deposits of IgG and
C3 in epidermal BM as well as neutrophil-rich leukocytic
infiltrates and subepidermal blisters
Grafts of Tg and Wt skin were placed on opposite flanks of
Wt, Tg, and MHC II/ recipients (n¼4 in each group of this
representative experimental set) and sampled by 3 mm punch
biopsies between 6 and 25 days after graft placement (i.e.,
before and during specific IgG production, as well as during
the time grafts displayed accelerated involution and loss). The
corresponding skin samples were studied by light and IF
microscopy, as described previously. All specific alterations
(i.e., those unrelated to wound reactions at the base and
margins of the grafts) were confined to Tg grafts on Wt
recipients. Such alterations were first noted approximately 17
days after graft placement and consisted of neutrophil-rich
leukocytic infiltrates within the papillary dermis and along
the epidermal BM (Figure 7a; Figure S1). A total of 20–25 days
after Tg skin was placed on Wt mice, all grafts showed
neutrophil-rich leukocytic infiltrates and edema within the
papillary dermis; half of these grafts showed clefting within
the epidermal BM and/or frank subepidermal blister forma-
tion (Figure 7b). Direct IF microscopy studies revealed in situ
deposits of murine IgG and C3 in the epidermal BMs of Tg
skin grafts on Wt recipients (Figure 7b). Immunoreactants
were not identified in the epidermal BMs of recipient skin
adjacent to, or at distance from, Tg grafts, or in control Wt
grafts placed on the opposite flanks of Wt (Figure 7b), Tg, or
MHC II/ recipients. The accumulation of immunoreac-
tants and neutrophil-rich leukocytic infiltrates in the epider-
mal BMs of Tg grafts on Wt mice displayed features
characteristic of immune complex-mediated tissue injury,
lesional skin from patients with BP, and neonatal murine skin
exposed to experimental IgG directed against the murine
homologue of the NC16A domain of hBPAG2.
Involution and loss of Tg skin grafts on CD4/ mice were
delayed and correlated with production of anti-BM IgG rather
than exposure to immune CD4þ T cells
Although light microscopy studies indicated that leukocytic
infiltrates in involuting Tg skin grafts on Wt recipients were
neutrophil rich, it was of interest to explore the possibility that
CD4þ T cells were contributing to the injury and loss of such
grafts. To address this question, Tg skin was grafted onto
CD4/ (and Wt, control) mice; recipients were followed for
anti-BM IgG production and graft viability. Of note, prior
studies showed that CD4/ mice possess a population of
CD4, CD8, abþ T cells that provide ‘‘help’’ in develop-
ment of specific antibody (Rahemtulla et al., 1994).
Longitudinal studies found that CD4/ mice grafted with
Tg skin consistently developed anti-BM IgG directed against
the epidermal side of 1 M NaCl split human skin (maximal
titers, 160–1,280) (Figure 8). In contrast to the kinetics of
specific IgG production in controls, anti-BM IgG production
in CD4/ mice was delayed, appearing between 42 and 52
days (mean, 47 days) after graft placement. Interestingly,
12–15 days following the detection of anti-BM IgG in
CD4/ recipients, Tg skin grafts displayed prompt involu-
tion and loss (Figure 8). In sum, while Tg skin grafts placed on
CD4/ mice survived longer than those placed on Wt
controls, the profiles of graft loss in both CD4/ and Wt
recipients displayed similar kinetics once IgG reactive with
the epidermal side of 1 M NaCl split human skin was detected
in their circulation.
To study further the potential role of CD4þ T cells in the
loss of Tg skin grafts, a series of adoptive transfer studies were
performed. In these studies, 5 106 naı¨ve CD4þ T cells from
Wt mice, or an equal number of ‘‘immune’’ CD4þ T cells
Tg graft on Wt recipient
Day 17
Day 22
TgTg
Donor
Wt
Wt
R
ec
ip
ie
nt
IgG C3
ControlControl
Figure 7. Tg skin grafts on wt recepients developed subepidermal blisters at
sites where in situ deposits of IgG and C3 were localized. (a) Tg and Wt skin
was grafted onto the opposite flanks of age and gender-matched Wt, Tg, and
MHC II/ recipients; biopsies were obtained between 6 and 25 days after
grafting for light and IF microscopy studies. All specific alterations (i.e., those
unrelated to wounds at the base and margins of grafts) developed in Tg grafts
on Wt recipients (shown here). Such alterations were evident as early as 17
days after grafting and consisted of neutrophil-rich infiltrates within the
papillary dermis. (b) Alterations in Tg skin grafts on Wt recipients progressed
to cleft and/or subepidermal blister formation within 20–25 days (top panels).
Direct IF microscopy revealed in situ deposits of murine IgG and C3 in
epidermal BMs of such grafts (arrows, bottom panels). Immunoreactants were
not identified in the epidermal BMs of recipient skin adjacent to, or at
distance from, Tg grafts, or in control grafts of Wt skin placed on the opposite
flanks of Wt (insets, bottom panels, dotted white lines outline epidermal BM),
Tg, or MHC II/ recipients. BarD25 mm.
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purified from the draining lymph nodes of Wt mice grafted
with Tg skin 10 days earlier were adoptively transferred to
separate sets of CD4/ mice. A day later, these mice (n¼ 4
per group) were engrafted with Tg skin. Recipients of naı¨ve or
‘‘immune’’ CD4þ T cells were then followed longitudinally
for evidence of anti-BM IgG production and graft viability.
CD4/ graft recipients infused with either naı¨ve or
‘‘immune’’ CD4þ T cells developed anti-BM IgG with a
kinetic profile like that seen in Wt mice grafted with Tg skin
(maximal titers, 160–1,280) (Figure 8). Graft loss in these
experimental groups displayed similar kinetics and again
followed the appearance of circulating anti-BM IgG by 12–15
days (Figure 8). The demonstration that anti-BM IgG
production and graft loss were the same in CD4/ mice
infused with either naı¨ve or ‘‘immune’’ CD4þ T cells
indicated that graft loss correlated better with the production
of specific IgG rather than the direct exposure of grafts to
CD4þ T cells (naı¨ve or ‘‘immune’’).
DISCUSSION
hBPAG2 Tg mice displayed a normal phenotype, life span,
and breeding capacity. Light, IF, and immunoelectron
microscopy studies showed that these mice expressed
hBPAG2 in murine epidermal BM with appropriate immuno-
reactivity and localization, and that this expression did not
impair the homeostasis of murine epidermis or the ultra-
structure of murine epidermal BM. Grafts of Tg skin placed on
Wt and MHC class I/ mice reliably elicited IgG that bound
epidermal BMs in human and Tg skin, but not the skin of Wt
mice. The production of anti-BM IgG in these mice
consistently occurred 14–18 days after graft placement and
was sustained for as long as 330 days. Grafts of Wt skin did
not elicit production of anti-BM IgG in syngeneic, gender-
matched recipients, showing that the grafting procedure itself
did not account for production of anti-BM IgG in Wt and
MHC class I/ mice grafted with Tg skin. Immunoblot and
immunoadsorption studies showed that the sera of Wt mice
grafted with Tg skin contained IgG that bound the immuno-
dominant NC16A domain as well as other epitopes within
hBPAG2. Immunoblot and immunoprecipitation studies
confirmed that IgG from Wt mice grafted with Tg skin bound
hBPAG2 but no other keratinocyte proteins including
BPAG1. Grafts of Tg skin did elicit production of low titers
of anti-BM IgM (but not anti-BM IgA) in Wt mice (data not
shown). Such IgM bound the epidermal side of 1 M NaCl split
human skin (titers o80), appeared in the circulation of graft
recipients within 15 days, and deposited in the epidermal
BMs of Tg skin grafts (data not shown). Tg skin grafts did not
elicit production of anti-BM IgG (or IgM) in MHC class II/
mice.
Tg skin grafts placed on Wt and MHC class I/ recipients
were consistently lost within 26–34 days. Accelerated graft
involution in these mice directly correlated with production
of anti-hBPAG2 IgG 14–18 days after graft placement.
Longitudinal and internally controlled clinical as well as
light and IF microscopy studies of Tg and Wt skin grafts
placed on the opposite flanks of Wt, Tg, and MHC class II/
recipients found that specific alterations were confined to Tg
skin grafts on Wt recipients. Such alterations were noted 17
days after graft placement, localized within the papillary
dermis, and consisted of neutrophil-rich leukocytic infiltrates
and dermal edema. Twenty to 25 days following graft
placement, light microscopy studies identified moderately
dense neutrophil-rich leukocytic infiltrates within the papil-
lary dermis, microscopic clefts within epidermal BM, and
frank subepidermal blister formation in grafted skin. These
alterations were not observed in: (1) Wt skin adjacent to, or at
distance from, involuting Tg skin grafts; (2) Tg skin grafts
placed on Tg or MHC class II/ recipients; or (3) Wt skin
grafts placed on gender-matched, syngeneic Wt, Tg, or MHC
class II/ recipients. All specific histologic alterations in
involuting Tg skin grafts on Wt recipients were focused at
sites where anti-BM IgG and C3 were deposited in graft
epidermal BMs. Just as there were no specific alterations in
recipient skin adjacent to, or distant from, involuting grafts,
all in situ deposits of immunoreactants were localized within
the epidermal BMs of Tg skin grafts. These histologic and
immunopathologic findings were characteristic of immune
complex-mediated tissue injury like those seen in lesional
skin from patients with BP, neonatal mice challenged with
experimental IgG directed against the murine homologue of
human NC16A, and cryosections of normal human skin
treated with IgG from patients with BP, a fresh source of
complement, and viable human neutrophils (Gammon et al.,
1982; Liu et al., 1993; Yancey and Egan, 2000; Sitaru et al.,
2002).
MHC class I/ mice grafted with Tg skin also developed
hBPAG2-specific IgG and graft loss of the same character
seen in Wt mice grafted with Tg skin. The lack of such
alterations in MHC class II/ mice grafted with Tg skin
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Figure 8. Loss of Tg skin grafts on CD4/ mice correlated with production
of anti-BM IgG. Longitudinal studies showed that Tg skin did elicit anti-BM
IgG in CD4/ recipients (solid circles), but that its production was delayed
(day 4475) in comparison to development of anti-BM IgG in Wt mice grafted
with Tg skin (day 1672). Accelerated graft loss in CD4/ recipients
correlated with production of anti-BM IgG and progressed to completion
within 12–15 days, a kinetic profile like that seen once specific IgG appeared
in the circulation of Wt mice grafted with Tg skin. Adoptive transfer studies
showed that involution and loss of Tg skin grafts on CD4/ recipients
infused with naı¨ve (solid squares) or ‘‘immune’’ (solid triangles) CD4þ T cells
correlated better with the development of anti-BM IgG than exposure to
CD4þ T cells. Arrows and brackets indicate the time points anti-BM IgG
appeared in the circulation of CD4/ mice engrafted with Tg skin.
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demonstrated that hBPAG2-specific IgG and graft loss were
dependent upon MHC class II:CD4þ T-cell interactions and
occurred independent of CD8þ T cells. Grafting studies in
CD4/ mice confirmed that such mice are capable of
specific IgG production and that graft involution and loss in
these recipients again correlated with development of anti-
hBPAG2 IgG. This conclusion was substantiated by showing
that the involution and loss of Tg skin grafts in CD4/ mice
infused with naı¨ve or immune CD4þ T cells correlated more
closely with hBPAG2-specific IgG production than the
administration of the T cells.
Previous studies demonstrated that skin allografts with a
major histocompatibility antigen difference can be rejected
within 14 days, while allografts differing in only a minor
histocompatibility antigen tend to be rejected more slowly
(Graff et al., 1966). The kinetics for loss of hBPAG2 Tg skin
grafts in this model approximated the median survival time of
skin grafts displaying experimental minor histocompatibility
antigens such as b-galactosidase, HIV-1 genome, or ovalbu-
min (median skin graft survival times ranging from 25 to 33
days) (Dumois et al., 1995; Valujskikh et al., 1999; Ehst et al.,
2003). Our experiments utilizing MHC I and II/ mice
demonstrated that CD8þ T cells were not responsible for
graft loss and that presentation of hBPAG2 on host antigen
presenting cells’ MHC II molecules was required for initiation
of specific IgG production and graft loss. In contrast to other
experimental grafting paradigms exploring responses to other
minor histocompatibility antigens, the loss of hBPAG2 Tg
skin grafts was not dependent upon the action of both CD4þ
and CD8þ T cells (Rees et al., 1990; Wettstein and
Korngold, 1992). Moreover, since CD4/ recipients lost
Tg grafts following development of hBPAG2-specigfic IgG,
CD4þ T cells in this model appear to be primarily
responsible for providing ‘‘help’’ for production of patho-
genic antibody.
Studies in this and other experimental models suggest that
ex vivo gene therapy approaches involving the introduction
of BPAG2 into the skin of EB patients who are ‘‘null’’ for this
protein may elicit humoral immune responses that are
undesirable and/or pathogenic (Lu and Ghazizadeh, 2005).
Findings in this model suggest that such responses would be
specific to tissue bearing hBPAG2. There was no evidence
that Tg skin grafts placed on Wt (or other) recipients led to a
break in tolerance to any other murine (or human) skin
protein. The consistent humoral immune response seen in Wt
mice grafted with Tg skin suggests that this experimental
model holds utility for the investigation of interventions that
may block, attenuate, or silence production of antibodies
directed against proteins in epidermal BM.
MATERIALS AND METHODS
Generation of an hBPAG2 transgene vector
Total RNA from subconfluent monolayer cultures of HKs was reverse
transcribed using random hexamers. The resulting cDNA was
amplified by PCR using 50 and 30 primers corresponding to regions
of hBPAG2 cDNA (GenBank accession number M91669). Multiple
cDNAs were produced and ligated to yield a 4.5 kb cDNA construct
corresponding to the entire length of hBPAG2. The latter was
sequenced verified and cloned into a modified pCMVb vector 30 to a
2.3 kb human keratin 14 promoter sequence (Shibaki et al., 2004).
The resulting vector included: (1) a single SV40 intron positioned
between the K14 promoter sequence and the hBPAG2 cDNA; and
(2) an SV40 polyadenylation sequence following the 30 end of the
hBPAG2 cDNA. The function of this construct, as well as the
integrity of its associated cDNA, was evaluated in transient
transfection studies of a HK line known to harbor null mutations in
COL17A1, the gene encoding BPAG2.
Transient transfection studies
Previous studies in our laboratory demonstrated that affected
individuals in a large Austrian kindred with GABEB were homo-
zygous for a two base pair deletion (4003delTC) in COL17A1
(McGrath et al., 1996; Darling et al., 1997b). This mutation results in
a premature termination codon 86 bp downstream that in turn leads
to nonsense-mediated mRNA decay. BPAG2 mRNA and protein
were not detectable in cultured keratinocytes (or epidermal BMs)
from such patients (Darling et al., 1997b). To develop a sustained
(and genotype-defined) source of BPAG2-null keratinocytes, mono-
layer cultures of HKs derived from an affected member of this
kindred were immortalized with an HPV16 E6/E7 construct. The
resulting HK line was subsequently passaged greater than 50 times
over a period of 12 months and stored in frozen aliquots. This
immortalized BPAG2-null HK line served as a relevant cell source
for characterization of our hBPAG2 transgene promoter and cDNA
construct in transient transfection studies.
Generation of hBPAG2 Tg mice
Following the verification experiments described above, the
transgene construct was linearized then microinjected into fertilized
oocytes of C57BL/6Ncr mice. The latter were subsequently
transplanted into pseudopregnant C57BL/6Ncr females to yield
chimeras. This approach was applied to yield Tg mice of a well-
characterized strain that (other than the transgene itself) would be
syngeneic to gender-matched Wt C57BL/6Ncr mice. All experi-
mental studies in animals were approved by the senior author’s
animal care and use committee.
Immunogold studies
Post-embedding immunoelectron microscopy of cryofixed and
cryosubstituted human, Tg, and Wt murine skin was performed as
described previously (Shimizu et al., 1989, 1992), with slight
modification. Small pieces of fresh skin were cryoprotected with
20% glycerol/phosphate-buffered saline at 41C for 30 minutes and
cryofixed by plunging into liquid propane cooled to 1901C (KF80,
Reichert-Jung, Vienna, Austria). Skin samples were cryosubstituted
(CS-auto, Reichert-Jung) with methanol at 801C for 120 hours and
embedded in Lowicryl K11M (Chemische Weke Lowi, Waldkraiburg,
Germany) at 601C. Specimens were polymerized by ultraviolet
irradiation at601C for 72 hours and at room temperature for another
72 hours. Ultra-thin sections were incubated 1 hour at 371C with
rabbit antiserum directed against the C-terminus of hBPAG2
(or normal rabbit serum (control), both at 1:2 dilution) (Masunaga
et al., 1997). After being washed, each section was placed on a drop
of 5 nm-gold-labeled goat anti-rabbit IgG (1:200 dilution) at 371C for
1 hour, then washed with distilled water. The sections were
counterstained with saturated uranyl acetate for 2 minutes.
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Skin grafting studies
Tail skin was harvested from Tg and Wt (control) C57BL/6Ncr mice
and grafted onto the backs of age- and gender-matched Wt and
C57BL/6Ncr control recipients (Rosenberg et al., 1994). The latter
included the following: B2m/ mice created by inactivation of the
-2 microglobulin gene, resultantly deficient in MHC I and lacking
mature CD8þ T cells (hereafter referred to as MHC I/) (Taconic,
Hudson, NY) (Zijlstra et al., 1990); Abb mice created by disruption of
the H2-Ab1 gene, resultantly deficient in MHC II and lacking mature
CD4þ T cells (hereafter referred to as MHC II/) (Taconic)
(Grusby et al., 1991); and Cd4tm1Mak mice created by targeted
mutation in the Cd4 gene, resultantly deficient in CD4þ T cells
(hereafter referred to as CD4/ mice) (Jackson Laboratories, Bar
Harbor, ME) (Rahemtulla et al., 1991). In some experiments, samples
of Tg and Wt skin were grafted onto opposite flanks on the same
recipient; in other experiments, recipients received only one graft.
Bandages were removed at day 7 and grafts were inspected daily
until day 30, then weekly, for viability and size. Skin grafts were
graded as ‘‘lost’’ if their area became 20% or less of their original
size (McFarland et al., 2003). Biopsies were obtained at various time
points 6–25 days after grafting and placed in 4% buffered formalin.
Such samples were embedded in paraffin, sectioned at 5 mm
thickness, stained with hematoxylin and eosin, and studied by light
microscopy. Matching biopsies were immediately placed in Tissue-
Tek OCT Compound (Miles Inc., Elkhart, IN), frozen, and stored at
701C; 6 mm cryosections of such samples were studied by direct IF
microscopy.
IF microscopy
Direct IF microscopy studies of murine skin cryosections were
performed as described previously using FITC-conjugated goat anti-
mouse Igs (reactive with IgG and IgM, cognate and crossreactive
antigens, respectively; the latter displaying 50% of the reactivity of
the former in comparative ELISAs (Biosource Inc., Camarillo, CA)),
FITC-conjugated rat anti-mouse IgG (Biosource Inc.), and FITC-
conjugated goat anti-mouse C3 (ICN Biomedicals, Aurora, OH)
(Lazarova et al., 1996). Serial dilutions of murine sera were tested
against cryosections of intact or 1 M NaCl split human skin (and in
selected experiments, intact murine skin) by indirect IF microscopy
as described previously (Lazarova et al., 1996). Second-step
antibodies included FITC-conjugated goat anti-mouse Igs and
FITC-conjugated rat anti-mouse IgG.
Complement fixation studies
Sera from Wt mice grafted with Tg skin (anti-BM IgG titers ranging
from 640 to 2,560) were tested for their ability to fix murine C3 to
epidermal BM in 1 M NaCl split skin, as described previously (Jordon
et al., 1976; Katz et al., 1976).
Immunoblotting
Cultured HKs and murine keratinocytes were extracted as described
previously (Labib et al., 1986; Roh et al., 2000). Constructs encoding
a NC16A-GST fusion protein (AA 490–562 of hBPAG2 (a gift from Dr
George Giudice, Medical College of Wisconsin)) or GST alone were
expressed in Escherichia coli strain DH5a and purified by
glutathione–agarose affinity chromatography using BugBuster
GST Bind Purification kit (Novagen, Madison, WI) (Giudice et al.,
1993). Keratinocyte extracts were reduced and applied to 6% Novex
Tris-Glycine SDS-polyacrylamide minigels (Invitrogen, Carlsbad,
CA); NC16A-GST and GST were reduced and applied to 4–12%
NuPage Bis–Tris SDS-polyacrylamide minigels (Invitrogen). Proteins
were transferred to nitrocellulose paper (Invitrogen) by electrophor-
esis and immunoblotted as described previously (Lazarova et al.,
1996; Roh et al., 2000). Alkaline phosphatase-conjugated goat anti-
mouse, anti-rabbit, or anti-human IgG (all at 1:1,000 dilution;
Biosource Inc.) were used as second-step antibodies. Immunoblots
were developed for 3 minutes (alkaline phosphatase-conjugate
substrate kit; Bio-Rad Laboratories, Hercules, CA) and then washed
extensively with Tris-buffered saline. Sera from patients with BP,
normal volunteers, mice grafted with Tg or Wt skin, Wt mice, a
rabbit immunized with recombinant hBPAG2, and a murine mAb
directed against human NC16A (HD-18) were studied by immuno-
blotting.
Immunoadsorption studies
Immunoadsorption was performed using a liquid phase protocol as
described previously (Martins et al., 1990). Immune sera diluted in
PBS were incubated with various concentrations of recombinant
GST or NC16A-GST at room temperature for 2 hours. Reaction
mixtures were microcentrifuged at 10,000 g for 15 minutes at 41C.
Immunoadsorbed sera were tested in: (1) immunoblot studies of HK
extracts and recombinant GST-NC16A; and (2) indirect IF micro-
scopy studies of 1 M NaCl split human skin.
Immunoprecipitation studies
Immunoprecipitation studies of biosynthetically radiolabeled HK
extracts were performed as described previously (Lazarova et al.,
1996).
Quantitation of antigen-specific T-cell proliferative responses in
Wt mice grafted with Tg skin
Tg skin was placed on both flanks of Wt recipients; 10 days later,
axillary and inguinal lymph nodes were collected, pooled, put into
suspension, and passed over a mouse CD4 subset column (R&D
Systems, Minneapolis, MN) to yield CD4þ T cells. CD4þ T cells
were plated at 2 105 cells/well in 96-well flat bottom microplates
(Costar, Corning Inc., Corning, NJ) in cRPMI 1640 containing 10%
heat-inactivated fetal calf serum supplemented with 50 mM 2-
mercaptoethanol (Sigma), 10 mM HEPES, pH 7.4, 2 mM glutamine,
100 U/ml penicillin, 100mg/ml streptomycin and 20 mg/ml genta-
mycin (all from Life Technologies, Chagrin Falls, OH). As stimulators,
splenocytes from naı¨ve C57BL/6Ncr mice were g-irradiated with
3000r and added to the CD4þ T cells at the concentration of
1 106 per well. Various concentrations of recombinant NC16A-
GST, GST alone, or PBS were added to the wells. On day 3 of
co-culture, [3H]thymidine (Amersham, Biosciences Corp., Piscataway,
NJ) (1mCi/well) was added and T-cell proliferative responses were
determined by the incorporation of [3H]thymidine during the last
16 hours of culture using a gas ionization counter (Packard, Meriden,
CT). Results are presented as the mean (7SEM) of assays performed
in triplicates.
Adoptive transfer studies
CD4/ mice received by intravenous injection 5 106 CD4þ
T cells (495% purity, R&D Systems) from naı¨ve or immune (i.e., 10
days previously grafted with Tg skin) Wt mice. The following day, Tg
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skin was placed on CD4/ recipients; mice were followed for anti-
BM IgG production and graft loss.
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SUPPLEMENTARY MATERIAL
Figure S1. Tg skin grafts on Wt recipients developed neutrophil-rich
leukocytic infiltrates and edema within the papillary dermis.
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